Market Segmentation:
- By Treatment Type
- Oral antifungals
- Topical antifungals
- Laser devices
- Photodynamic therapy
- Surgical/chemical nail avulsion
- Others
- By Route of Administration
- Oral
- Topical
- Injectable
- Others
- By Distribution Channel
- Hospitals & Clinics
- Dermatology Centers
- Retail & Online Pharmacies
- Others
- By Infection Type
- Distal subungual onychomycosis
- White superficial onychomycosis
- Proximal subungual onychomycosis
- Candidal onychomycosis
- Total dystrophic onychomycosis
- Others
- By Causative Agent
- Dermatophytes
- Non-dermatophyte molds
- Yeasts
- Others
- By Regions
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The current market size of the Onychomycosis industry is around USD 4.6 billion in 2023.
Rising geriatric population, Increasing prevalence of diabetes, Growing awareness about treatment, Advancements in diagnostics, Shift towards combination therapies, Strong product pipeline
Low diagnosis rates, high treatment costs, failure of monotherapies, need for prolonged treatment duration, adverse effects of antifungals, patient non-compliance, generic competition, reimbursement challenges, lack of curative therapies, social stigma surrounding nail disorders, limited awareness about treatment options.
The leading component segment in the Onychomycosis Market is oral antifungals.
Bayer, Pfizer, Novartis, Johnson & Johnson, Valeant Pharma, Galderma, Kaken Pharmaceutical, GlaxoSmithKline, Merz Pharma, Vyome Biosciences, Moberg Pharma, Polichem, Medimetriks Pharmaceuticals, NovaBiotics, Mayne Pharma, Lumenis, Biofrontera.
The Onychomycosis Market is projected to reach USD 6.9 billion by 2031 from USD 4.6 billion in 2023, at a CAGR of 5.2% during the forecast period.
Rising geriatric population, Increasing diabetes prevalence, Growing awareness about treatment options, Advancements in diagnostics.